PHARMA 4.0
 

Pharma 4.0, 2019年3月19日(二)

08:45

Organiser’s welcome Remarks

Joe Zhou
08:50

Chair’s opening Remarks

Joe Zhou, Chief Executive Officer, Genor BioPharma, Walvax Group

Opening Keynote Plenary

David Lane
09:00

Going global and keeping it local: Is biotech innovation sustainable in Asia?

In this keynote presentation, Sir David Lane, one of the key scientists credited on the discovery of cancer gene p53, a gene which mutation cause near 50% of all human cancer, will share his view on how biomedical sciences have developed in Singapore, Japan and the remaining APAC region, and prospects for Asian biotech and pharma industry.
David Lane, Chief Scientist, Agency for Science, Technology and Research (A*STAR)
Byung-Geon Rhee
09:20

Looking east: Integrating Asia into the global era of innovative medicine

Byung-Geon Rhee, Chief Executive Officer, SCM Lifescience
Panel discussion
09:40

Pharma Trends: Women health as the next focus

Women’s health goes beyond mother & childcare. For instance, women has a higher risk of cardiovascular diseases compared to men, hence there is a need to invest more on addressing the biological differences in mainstream disease studies to ensure a more effective, personalised treatment. In addition, big data & AI application on female subjects may also differ from male subjects, prompting a need to investigate how studies should be developed differently in the future. This panel brings experts to debate and discuss how femtech is shaping to be the next global pharma focus and the new areas of focus in women's healthcare.
Moderator: Reenita Das, Partner, Frost & Sullivan
Evelyn Pang, Head Of Operations, Sanofi Pasteur
Marcel Van Duin, VP Research, Therapeutic Area Head, Reproductive Medicine & Women's Health, Ferring Pharmaceuticals
10:20

Speed networking & Networking Refreshment

PHARMA 4.0: DRUG DEVELOPMENT

James Garner
Pharma 4.0
11:15

Chair's opening remarks

James Garner, Chief Executive Officer And Managing Director, Kazia Therapeutics Limited
Reenita Das
Pharma 4.0
11:20

The transformation of the Bio pharma industry. Top growth opportunities for 2025

Reenita Das, Partner, Frost & Sullivan
Henry Ines
Pharma 4.0
11:40

Increasing transparency and knowledge-sharing efficiency with blockchain

Henry Ines, Chief Executive Officer, Shivom.io
Gavin Teo
Pharma 4.0
12:00

AI- enhanced drug development platforms

Gavin Teo, General Partner, B Capital Group
T Balganesh
Pharma 4.0
12:20

Innovative strategies to cope with the rise of superbugs

T Balganesh, President, GangaGen
12:40

Exhibition Visit & Networking Lunch

Raphael Aswin Susilo
Pharma 4.0
12:40

R&D Management: Additional value enhancement through innovation

Raphael Aswin Susilo, Vice President - Research And Development, Regulatory And Medical Affairs, Soho Global Health

PHARMA 4.0: DIGITAL SUPPLY

Pharma 4.0
14:10

Chair’s opening remarks

Jason Tamara Widjaja
Pharma 4.0
14:20

Building an in-house pharma AI product team: Key steps & considerations

  • In-house vs outsource: What are the key benefits & challenges in building in-house data science projects
  • Ethics in consideration: How to make AI products more neutral and non-discriminative
  • Why data science project fails and how do we prevent it?
Jason Tamara Widjaja, Associate Director, Global Data Science (Ai And Data Products), msd
Pharma 4.0
14:40

Reserved for sponsor

Kamal Amin
Pharma 4.0
15:00

Reshaping your supply chain to address supply shortage: A patient-centric approach

Kamal Amin, Senior Clinical Supply Manager, Fujifilm Kyowa Kirin Biologics
Pharma 4.0
15:20

From data to drug: Improving your supply chain with emerging technology

Interviewee: Kamal Amin, Senior Clinical Supply Manager, Fujifilm Kyowa Kirin Biologics
Interviewer: Nitin Jain, Vice President, Asia-Pacific, ANCILLARE, LP
15:40

Exhibition Visit & Networking Refreshments

PHARMA 4.0: NEXT GENERATION COMMERCIAL PARTNERSHIP MODELS

Robert Wonsang Yu
Pharma 4.0
16:40

Scaling new heights: Fast-tracking success in Asia with open innovation and new partnership opportunities

Robert Wonsang Yu, Vice President, Yuyu Pharma
Joe Zhou
Pharma 4.0
17:00

Partnering through acquisition: How new M&A trends in Asia are fostering innovation

Joe Zhou, Chief Executive Officer, Genor BioPharma, Walvax Group
Gopal Rao
Pharma 4.0
17:20

Breaking the boundary of traditional B2B partnership: Next generation pharma-PE/VC model

Gopal Rao, Global Business Development And Services Outsourcing, Biotech Division Lupin Ltd
17:40

Networking Cocktail & End of Conference Day 1

last published: 17/Jan/19 09:15

Pharma 4.0, 2019年3月20日(三)

08:45

Organiser’s welcome Remarks

08:50

Chairman’s opening Remarks

Nadia Suttikulpanich
09:00

Disrupt before being disrupted: Using digital tech to connect to previously uneconomic chronic disease customers

Insurance is a tricky part of healthcare business. Increased healthcare costs lead to a higher profit for pharma and provider companies but burdens the government budget and hurts the insurance business. Since taking care of a chronic patient is a lifelong commitment, the availability of insurance to cover this essential treatment is often expensive and uneconomical. Join Nadia Suttikulpanich, Head of the Fuchsia Innovation Center, part of Muang Thai Life Assurance, Thailand as she shares how they are adopting digital tech to pilot chronic disease cover to provide for patients in need while keeping their insurance business profitable.
Nadia Suttikulpanich, Head Of Fuchsia Innovation Center For Muang Thai Life Assurance, Muang Thai Life Assurance Public Company
Edward Rosen
09:20

The path to personalised medicine: Key developments

Everyone knows the potential benefits of personalised medicine, but how do we get there? Finding and better defining disease through biomarkers and more accurate diagnostics. Targeted therapeutics to leverage new and emerging diagnostic capabilities. Personalized Medicine to Real-Time Medicine. How to drive success across industry and clinical implementation in an economic manner. This presentation discusses various strategies and key considerations to drive the symbiosis between academia, industry and clinical medicine to drive vastly improved patient outcomes.
Edward Rosen, Leader, Glendevon Life Sciences LLC & Executive in Residence, Columbia Technology Ventures
Panel discussion
09:40

Pharma 4:0 Digital disruption: New players, new opportunities

Moderator: Shwen Gwee, General Manager, Digital Accelerator (Global Drug Development), Novartis
Teck Jack Tan, Chairman And Medical Director, Northeast Medical Group
Matt Cooper, Business Development And Research Director, NIHR Clinical Research Network
Andreas Koester, Vice President Of Clinical Trial Innovation And External Alliances, Johnson & Johnson
David Benshoof Klein, Chief Executive Officer, Click Therapeutics
Raghu Bathina, Founder, Future World Studios
10:20

Roundtable discussion

Table 1 Working with clinical outsourcing partners: Risk management and prevention

Pei Yin Tan, Director, Asia Clinical Operations, Medicine Development Center, Eisai Clinical Research Singapore Pte Ltd

Table 2 Fostering commercial partnerships to tap on emerging APAC markets

Charles Stacey, President And Chief Executive Officer, Cerecin

Table 3 Regulatory collaboration and opportunities in more efficient drug development

Phusit Prakongsai, Ministry of Public Health Thailand

Table 4 Strategies in making drugs more affordable and accessible to patients in developing countries

Pratapa Satyanarayana, Former Senior Director And Group Country Head, Dr. Reddy?s Laboratories Ltd.

Table 5 Universal healthcare- Is it really costly?

Table 6 A convergent approach: Tapping on western expertise to serve Asia population

Philippe Pinton, Regional Head, Specialty Therapy, Takeda

Table 7 Precision to personalised medicine- How do we get there?

Mrunalini Jagtap, Data Management Lead, SICS, A*STAR

Table 8 Leveraging blockchain technology in making clinical trials more transparent and efficient

Table 9: Data Science in practice: How can sales reps and MSLs use Big Data?

Prabhuram Krishnan, South Asia Medical Director, Ipsen Pharma

Table 10: The Singapore biotech ecosystem - What comes after the Inflexion?

11:00

Exhibition Visit & Networking Refreshments

PHARMA DATA & PREDICTIVE ANALYTICS

Ogan Gurel
Pharma 4.0
11:40

Role of big data and bioinformatics in precision medicine

Ogan Gurel, Chief Executive Officer And Founder, NovumWaves
Andreas Koester
Pharma 4.0
12:00

Innovating with the patient for the patient: Using data for patient engagement in clinical trials

Andreas Koester, Vice President Of Clinical Trial Innovation And External Alliances, Johnson & Johnson
Pharma 4.0
12:20

Data Science at the Frontlines: How can we use Big Data to showcase pharma's value to stakeholders?

Dean Ho
Pharma 4.0
12:40

Breaking the predictive analytics model: Using small data for targeted therapeutics

Dean Ho, Co-Founder, KYAN Therapeutics
13:00

Exhibition Visit & Networking Lunch

PHARMA 4.0: PATIENT CENTRICITY

Pharma 4.0
14:30

Using digital platforms and social media for better patient engagement

Nathanael Faibis
Pharma 4.0
14:50

Remote patient management solutions for better engagement

Nathanael Faibis, Founder And Chief Executive Officer, Alodokter
Raghu Bathina
Pharma 4.0
15:10

Virtual Reality for patient care and engagement

Raghu Bathina, Founder, Future World Studios

PHARMA 4.0: DIGITAL THERAPEUTICS

David Benshoof Klein
Pharma 4.0
15:30

Complement or replacement? Envisioning the future of digital therapeutics

David Benshoof Klein, Chief Executive Officer, Click Therapeutics
Teng Yan Yau
Pharma 4.0
15:50

Using real world data in digital intervention

Teng Yan Yau, Chief Medical Officer, Holmusk
Bechara Saab
Pharma 4.0
16:10

Choosing the right business model for digital therapeutics

Bechara Saab, Chief Executive Officer and Chief Scientist, Mobio Interactive
16:30

End of Phar-East 2019

last published: 17/Jan/19 09:15

* 活動內容有可能不事先告知作更動及調整。